

Insights into the Brain Clearance Mechanisms of Oligomeric Beta-Amyloid Species

<https://www.neurodegenerationresearch.eu/survey/insights-into-the-brain-clearance-mechanisms-of-oligomeric-beta-amyloid-species/>

Principal Investigators

GHISO, JORGE A

Institution

NEW YORK UNIVERSITY SCHOOL OF MEDICINE

Contact information of lead PI

Country

USA

Title of project or programme

Insights into the Brain Clearance Mechanisms of Oligomeric Beta-Amyloid Species

Source of funding information

NIH (NIA)

Total sum awarded (Euro)

427637.6147

Start date of award

15/08/2015

Total duration of award in years

2

Keywords

Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Brain Disorders... Cerebrovascular... Dementia... Neurodegenerative... Neurosciences

Research Abstract

? DESCRIPTION (provided by applicant): Synaptic pathology- one of the strongest correlates to cognitive impairment- is related to the progressive accumulation of oligomeric forms of neurotoxic A β . The assembly of A β monomers into oligomers is a concentration-dependent process and as such, it is dependent on adverse changes that alter homeostatic mechanisms

regulating A β physiologic levels in the interstitial fluid (ISF), such as impaired normal brain removal and/or deficient catabolism. Surprisingly, very little is known about the brain clearance and local catabolism of A β oligomers, particularly during the aging process. Based on a wealth of preliminary/feasibility data we propose to start filling this gap in knowledge by bridging together different understudied aspects of these processes: i) the poorly recognized high heterogeneity of the brain A β species, with multiple N- and C- terminally truncated derivatives co-existing with the classic full-length duo A β 40/A β 42; ii) the ability of local brain resident enzymes to efficiently generate these truncated fragments; iii) the remarkable dissimilarities of these species in solubility and oligomerization propensity, suggesting engagement in opposite mechanisms either amyloidogenesis or clearance; and iv) the negative impact that aging imposes to anatomical and functional components of the clearance pathway e.g. compromised vascular integrity, lower density of cellular A β transporters, substandard performance of the local proteolytic machinery all likely affecting the brain efflux efficiency of the perivascular drainage, as well as through the blood-brain and brain-CSF barriers. The presence of already established amyloid deposits a seldom considered complication further obscures the clearance scenario, not only through the potential recruitment of soluble A β species to the lesions but by additionally restricting vessel functionality, contributing to the self-perpetuation of the amyloidogenic loop. We hypothesize that the process of amyloidogenesis goes beyond the simplistic dichotomy A β 40/A β 42, involving locally generated pro-oligomeric truncated fragments and differential in vivo brain clearance for monomeric and oligomeric A β species likely mediated by the efflux transporters LRP-1 and P-gp, and postulate that these mechanisms are negatively modulated by aging and by the presence of pre-existing amyloid deposits. Assembled in two specific aims, we propose to compare the physiologic in vivo brain clearance of monomeric and oligomeric forms of intact and truncated A β species, evaluate their local catabolism and relevance of A β -efflux transporters while assessing the differential effect that normal aging and the presence of already established amyloid deposits exert in the brain removal mechanisms. Through the use of radiolabeled and isotopically-labeled A β homologues, stereotaxic intra-hippocampal injections in wild-type mice and APP^{swe}PS1^{dE9} transgenics, novel specific antibodies, targeted proteomic/mass spectrometry approaches in mouse CSF, and in vitro cell culture paradigms, the project will provide a better understanding of brain A β catabolism and clearance in health and disease.

Further information available at:

Types:

Investments < €500k

Member States:

United States of America

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A